The prognostic significance of FOXP3 expression in patients with metastatic HER2-positive breast cancer DOI Creative Commons
О. І. Vynnychenko, Yuliia Moskalenko, Roman Moskalenko

и другие.

The Journal of V N Karazin Kharkiv National University series Medicine, Год журнала: 2024, Номер 51, С. 495 - 504

Опубликована: Дек. 30, 2024

Background. The effectiveness of targeted therapy in patients with HER2+ breast cancer largely depends on the tumor microenvironment. Regulatory T-lymphocytes (FOXP3+) negatively regulate immune responses and are mostly considered a factor unfavorable prognosis. Breast is heterogeneous disease unique biological properties for each molecular subtype. impact regulatory T cells prognosis controversial. Purpose – to evaluate prognostic significance metastatic cancer. Materials Methods. study included 78 who were treated at Sumy Regional Clinical Oncology Center from 2014 2024. Data clinical pathological characteristics taken primary medical documentation. Immunohistochemistry was performed all samples tissue. lymphocytes visualized using antibodies against FOXP3. Pearson test, One-way ANOVA, Kaplan–Meier method, logarithmic test used statistical analysis. Local Ethics Committee approved study. Results. mean age low high Foxp3 expression 53.1 ± 1.74 57.3 1.64, respectively. Among expression, there proportion women younger than 50 years (p = 0.0423) estrogen-negative (χ2 8.4080, p 0.023). Other clinicopathological patients, such as location tumor, histopathological diagnosis, grades, visceral non-visceral metastases, Ki67 proliferation index, did not show an association expression. Median progression-free survival 12.9 months 15.5 respectively (Log-rank 0,0001). overall 21.6 46.9 Conclusions. In cancer, associated better survival. those FOXP3 under more prevalent.

Язык: Английский

Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis DOI

Baofa Yu,

Wenxue Ma

Cytokine & Growth Factor Reviews, Год журнала: 2024, Номер 79, С. 29 - 38

Опубликована: Авг. 24, 2024

Язык: Английский

Процитировано

9
Association of Proteasome Activity and Pool Heterogeneity with Markers Determining the Molecular Subtypes of Breast Cancer DOI Open Access
И. В. Кондакова, E. E. Sereda, E. A. Sidenko

и другие.

Cancers, Год журнала: 2025, Номер 17(1), С. 159 - 159

Опубликована: Янв. 6, 2025

Background: Proteasomes degrade intracellular proteins. Different proteasome forms were identified. Proteasome inhibitors are used in cancer therapy, and novel drugs directed to specific developed. Breast (BC) therapy depends on the subtype of tumor, determined by expression level Ki67, HER-2, estrogen progesterone receptors. Relationships between presence proteins that determine BC remain unclear. Here, using gene data 19,145 tumor samples from 144 datasets tissues 159 patients with different subtypes BC, we investigated association activity proteasomes levels markers. Methods: Bioinformatic analysis subunit (PSMB1-10) was performed. heterogeneity cell lines qPCR. By Western blotting, composition assessed cells patient tissue lysates. activities studied fluorogenic substrates. molecular immunohistochemistry. Results: demonstrate differing pattern strong PSMB8-10 co-correlation tumors. A significant increase chymotrypsin- caspase-like compared adjacent revealed. The varied. Regression demonstrated a positive correlation receptors Conclusion: differences within pool. Correlations activity, hormone Ki67 indicate possible mutual influence. Obtained results facilitate development drug combinations for therapy.

Язык: Английский

Процитировано

0
Evaluating the correlation between pretreatment 18F-FDG PET/CT metabolic parameters and tumor-infiltrating lymphocyte levels in nonluminal breast cancer and impact on survival DOI Creative Commons
Müge Öner Tamam, Halim Özçevik,

Gamze Kulduk

и другие.

Pathology & Oncology Research, Год журнала: 2025, Номер 30

Опубликована: Янв. 8, 2025

Язык: Английский

Процитировано

0
Reverse-engineering the FLT3-PI3K/AKT axis to enhance TILs function and improve prognosis in ovarian and cervical cancers DOI Creative Commons
Hao Feng, Yan Zhang,

Lili Shen

и другие.

Journal of Ovarian Research, Год журнала: 2025, Номер 18(1)

Опубликована: Янв. 25, 2025

Ovarian cancers (OC) and cervical (CC) have poor survival rates. Tumor-infiltrating lymphocytes (TILs) play a pivotal role in prognosis, but shared immune mechanisms remain elusive. We integrated single-cell RNA sequencing (scRNA-seq) spatial transcriptomics (ST) to explore regulation OC CC, focusing on the PI3K/AKT pathway FLT3 as key modulators. Seurat Harmony were employed for batch correction dimensionality reduction. expression was mapped with data from 10 × Genomics. FLT3, identified regulator through pathway, showed positive correlations T cells, NK B cells. FLT3-high regions exhibited increased infiltration, particularly enhancing outcomes. This study provides first spatially resolved evidence of FLT3's immune-modulatory positioning it promising immunotherapeutic target. FLT3-targeted strategies may offer new options patients resistant conventional therapies.

Язык: Английский

Процитировано

0
Identification of immune infiltration-related ZNF480 for predicting prognosis in breast cancer DOI
Tong Zhou,

Yanqiu Zhang,

Jun Cao

и другие.

American journal of clinical and experimental immunology., Год журнала: 2025, Номер 14(1), С. 1 - 13

Опубликована: Янв. 1, 2025

Breast cancer is one of the most common cancers in women with high morbidity and mortality. ZNF480, a member KRAB-ZNFs family, correlates progression. However, its role development progression breast remains unclear. We utilized transcriptomic clinical data from The Cancer Genome Atlas (TCGA) Genotype Tissue Expression (GTEx) databases patients to investigate potential pro-cancer including differential expression ZNF480 cancer, prognostic value, clinicopathological features, immune cell infiltration relevance function enrichment analysis. Our results indicate that upregulated correlations survival, stage, race tumor subtype patients. Additionally, analysis revealed significant negative between multiple infiltrating cells, aDC, B CD8 T Cytotoxic DC, iDC, Macrophages, Neutrophils, NK CD56bright CD56dim pDC, Tem, TFH Th1 whereas positive correlation was observed helper Tcm, Tgd Th2 cells. Furthermore, functional indicated may be involved Angiogenesis, Allograft rejection, TNFα signaling via NFκB, Coagulation, IL6 Jak STAT3 signaling, Inflammatory response, Interferon gamma response other processes. highly expressed infiltration, candidate biomarker, which assist treatment.

Язык: Английский

Процитировано

0
Prospects for the use of CAR-T-cell therapy in breast cancer: A look into the future DOI Creative Commons
Л. Е. Сорокина,

A. L. Nezlina,

А. М. Krasnyi

и другие.

Регенерация органов и тканей., Год журнала: 2025, Номер 2(2), С. 10 - 23

Опубликована: Март 22, 2025

Cellular immunotherapy CAR-T (Chimeric Antigen Receptor T-Cell, or T-cells with a chimeric antigen receptor) is an advanced approach to the treatment of oncological diseases. Currently, CAR-Ttherapy has shown high efficiency in oncohematological At same time, numerous attempts create CAR-T-constructs for solid tumors, particular breast cancer (BC), have not demonstrated significant clinical efficacy. It assumed that key solving these problems lies development and implementation new genetic engineering strategies.The purpose this review was summarize systematize existing studies CAR technology. In paper, we potential targets BC, detail limitations using technologies identify important future trends area.

Язык: Английский

Процитировано

0
Present and Future of Immunotherapy for Triple-Negative Breast Cancer DOI Open Access

Sushmitha Sriramulu,

Shivani Thoidingjam, Corey Speers

и другие.

Опубликована: Авг. 14, 2024

Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptors, human epidermal growth factor receptor 2, and progesterone receptors (PR). TNBC has poorest prognosis among subtypes is more likely to respond immunotherapy due its higher PD-L1 a greater percentage tumor-infiltrating lymphocytes. Immunotherapy revolutionized treatment, especially with FDA's approval pembrolizumab (Keytruda) combined chemotherapy for advanced cases, opening new avenues treating this deadly disease. Although, can significantly improve patient outcomes in subset patients, achieving desired response rate all remains an unmet clinical goal. Strategies that responses immune checkpoint blockade, including combining chemotherapy, molecularly targeted therapy, or radiotherapy may rates outcomes. In review, we provide short background on explore different types strategies are currently being evaluated TNBC. Additionally, review why combination be beneficial, overview strategies, discuss novel immunotherapeutic opportunities approved near future

Язык: Английский

Процитировано

3
Advancements in tumor-infiltrating lymphocytes: Historical insights, contemporary milestones, and future directions in oncology therapy DOI

Muhammad Talha Aizaz,

Alina Sami Khan, Maria Khan

и другие.

Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 202, С. 104471 - 104471

Опубликована: Авг. 8, 2024

Язык: Английский

Процитировано

1
Evolving immunotherapeutic solutions for triple-negative breast carcinoma DOI
Shiting Wu, Anqi Ge, Xianguang Deng

и другие.

Cancer Treatment Reviews, Год журнала: 2024, Номер 130, С. 102817 - 102817

Опубликована: Авг. 17, 2024

Язык: Английский

Процитировано

1
Tumor-Associated Neutrophils Are a Negative Prognostic Factor in Early Luminal Breast Cancers Lacking Immunosuppressive Macrophage Recruitment DOI Open Access

Eva Schmidt,

Luitpold Distel, Ramona Erber

и другие.

Cancers, Год журнала: 2024, Номер 16(18), С. 3160 - 3160

Опубликована: Сен. 15, 2024

Background: Tumor-associated neutrophils (TANs) are important modulators of the tumor microenvironment with opposing functions that can promote and inhibit progression. The prognostic role TANs in early luminal breast cancer is unclear. Methods: A total 144 patients were treated for early-stage hormone-receptor-positive as part an Accelerated Partial Breast Irradiation (APBI) phase II trial. Resection samples from multiple locations processed into tissue microarrays sections thereof immunohistochemically stained CD66b+ neutrophils. neutrophil density was measured separately stromal intraepithelial compartment. Results: High TAN a negative factor central samples. In addition, adjacent normal lymph node also correlated reduced disease-free survival. CD163+ M2-like tumor-associated macrophage (TAM) density, which we analyzed previous study. tumors elevated M1/M2 TAM ratio, while this impact on patient outcome lost low ratio. combined multivariate analysis revealed only polarization status independent factor. Conclusions: single-marker analysis. Combined TAMs could be necessary to correctly evaluate their future studies. recruitment might act compensatory mechanism immunoevasion disease progression unable sufficiently attract polarize TAMs.

Язык: Английский

Процитировано

1